Chordoma: current concepts, management, and future directions

Lancet Oncol. 2012 Feb;13(2):e69-76. doi: 10.1016/S1470-2045(11)70337-0.


Chordoma is a rare bone cancer that is aggressive, locally invasive, and has a poor prognosis. Chordomas are thought to arise from transformed remnants of notochord and have a predilection for the axial skeleton, with the most common sites being the sacrum, skull base, and spine. The gold standard treatment for chordomas of the mobile spine and sacrum is en-bloc excision with wide margins and postoperative external-beam radiation therapy. Treatment of clival chordomas is unique from other locations with an enhanced emphasis on preservation of neurological function, typified by a general paradigm of maximally safe cytoreductive surgery and advanced radiation delivery techniques. In this Review, we highlight current standards in diagnosis, clinical management, and molecular characterisation of chordomas, and discuss current research.

Publication types

  • Review

MeSH terms

  • Bone Neoplasms / diagnosis*
  • Bone Neoplasms / pathology
  • Bone Neoplasms / therapy*
  • Chordoma / diagnosis*
  • Chordoma / pathology
  • Chordoma / therapy*
  • Clinical Trials, Phase I as Topic
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Prognosis
  • Rare Diseases / diagnosis*
  • Rare Diseases / pathology
  • Rare Diseases / therapy*
  • Receptors, Platelet-Derived Growth Factor / metabolism
  • Spine / pathology
  • Treatment Outcome


  • Receptors, Platelet-Derived Growth Factor